Ronkoleikin - instructions for use, reviews, analogs and forms of release (injections in ampoules for injections and infusions of 250, 500 and 1,000,000 IU) of a drug for the treatment of immunodeficiency, pneumonia, cancer in adults, children and in pregnancy

In this article, you can read the instructions for using the drug Roncoleukin. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Ronkoleikin in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues Roncoleukin in the presence of existing structural analogs.Use for the treatment of immunodeficiency, pneumonia, cancer in adults, children, as well as during pregnancy and lactation.

Roncoleukin - recombinant interleukin-2 (rIL-2), a structural and functional analogue of endogenous interleukin-2 (IL-2).

IL-2 is produced by a subpopulation of T-lymphocytes (T-helpers 1) in response to antigenic stimulation. Synthesized IL-2 affects T-lymphocytes, enhancing their proliferation and subsequent synthesis of IL-2.

The biological effects of IL-2 are mediated by its binding to specific receptors represented on various cellular targets.

IL-2 has a direct effect on the growth, differentiation and activation of T- and B-lymphocytes, monocytes, macrophages, oligodendroglial cells, Langerhans cells. From its presence depends the development of cytolytic activity of natural killers and cytotoxic T-lymphocytes. IL-2 causes the formation of lymphokine-activated killers and activates tumor-filtering cells.

Expansion of the spectrum of the licking action of effector cells causes the elimination of a variety of pathogenic microorganisms, infected and malignant cells, which provides immune protection directed against tumor cells,as well as pathogens of viral, bacterial and fungal infections.

Composition

Interleukin-2 human recombinant + auxiliary substances.

Indications

As part of complex therapy in adults:

• usual variable immunodeficiency;
• combined immunodeficiency;
• acute peritonitis;
• acute pancreatitis;
• osteomyelitis;
• endometritis;
• severe pneumonia;
• sepsis;
• postpartum sepsis;
• pulmonary tuberculosis;
• other generalized and severe localized infections;
• infected thermal and chemical burns;
• Disseminated and locally advanced forms of renal cell carcinoma.

As part of complex therapy in children from 0 years:

• usual variable immunodeficiency;
• combined immunodeficiency;
• acute peritonitis;
• acute pancreatitis;
• osteomyelitis;
• severe pneumonia;
• bacterial sepsis of newborns;
• sepsis;
• other generalized and severe localized infections.

Forms of release

Solution for infusions and subcutaneous injection (injections in ampoules for injections) 250 thousand IU, 500 thousand IU and 1 million IU.

Instructions for use and dosage

Roncoleukin is administered 1 time per day subcutaneously or intravenously drip (in the form of a dropper) at 0.5-1.0 mg at intervals of 1-3 days, on the course - 1-3 administration.For intravenous administration, the drug from the ampoule is transferred to 400 ml of isotonic sodium chloride solution for injection. Infusion of the entire volume of the solution is carried out dropwise for 4-6 hours.

The drug solution should be clear, colorless and free of foreign inclusions.

The immunotherapy with Roncoleukin is carried out after the completion of urgent and urgent surgical interventions aimed at eliminating the life-threatening consequences of the underlying disease / trauma, sanation and adequate drainage of the infectious focus.

In the treatment of severe sepsis, 1 to 3 courses of treatment with Roncoleukin are given. The course includes 2 intravenous infusions at a dose of 0.5 mg every other day. The criterion for prescribing the second and third courses of treatment with Roncoleukin is the lymphopenia (absolute and / or relative) that persists during treatment.

At the first time revealed infiltrative destructive pulmonary tuberculosis - 3 intravenous infusions of Roncoleukin 0.5 mg at intervals of 48 h against specific polychemotherapy.

For preoperative preparation with progressing fibrous-cavernous tuberculosis (FCT) of the lungs against a background of specific polychemotherapy: for unilateral FCT-3 in / in the administrationpreparation Roncoleukin 1 mg at intervals of 48 hours; in case of widespread pulmonary tuberculosis with bilateral focal dissemination, 7 intravenous injections of Roncoleukin: 3 administrations during the first week of 1 mg at intervals of 48 hours, then 1 mg twice a week for 2 weeks. The recommended course of immunotherapy should be completed 7-10 days before surgery.

The appointment of the drug Roncoleukin for pulmonary tuberculosis is inappropriate with a body weight deficit of more than 30%.

The course of treatment with the Roncoleukin preparation of disseminated and locally advanced forms of renal cell carcinoma includes:

• single sc or iv dose of 0.5 mg for 24 hours before surgery;
• as part of an 8-week immunochemotherapy course of 2.0 mg IV every other day for the first 4 weeks of treatment. Repeated courses take place after 1-2 months.

In children, Roncoleukin is administered intravenously drip. Schemes of application correspond to those of adults. The drug is diluted in isotonic (0.9%) sodium chloride solution. A single dose of the drug and the volume of isotonic solution in children depends on the age:

• from 0 to 1 month. - 0.1 mg in 30-50 ml of solution;
• from 1 month. up to 1 year - 0.125 mg in 100 ml of solution;
• from 1 year to 7 years - 0.25 mg in 200 ml of solution;
• over 7 years - 0.5 mg in 200 ml of solution;
• over 14 years - 0.5 mg in 400 ml of the solution.

Side effect

• the appearance of a short-term chill and an increase in body temperature during the administration of Roncoleukin, which is stopped by conventional therapeutic agents and is not grounds for interrupting the administration of the drug, as well as the abolition of therapy;
• with subcutaneous administration of the drug: soreness, tightness, redness at the injection site.

Contraindications

• autoimmune diseases;
• heart failure 3 items;
• pulmonary heart failure 3 items;
• metastatic brain damage;
• terminal stage of renal cell carcinoma;
• pregnancy;
• hypersensitivity to yeast;
• increased sensitivity to interleukin 2 or any component of the drug in history.

Application in pregnancy and lactation

The drug Roncoleukin is contraindicated in pregnancy.

Use in children

Possible use according to indications (including infants and newborns) starting from 0 years.

special instructions

With caution use the drug for chronic kidney failure, decompensated hepatic insufficiency.

Special dosage form Roncoleukin 50.000 IU is used in veterinary medicine in cats and dogs for the treatment of infectious and inflammatory processes, normalization of immunity, neutralization of the effects of stress and vaccinations in animals.

Impact on the ability to drive vehicles and manage mechanisms

Special studies of the effect of the drug on the ability to drive vehicles and use complex equipment were not carried out. In the case of unwanted reactions on the part of the visual organ and / or a decrease in the ability to concentrate and respond quickly, patients are advised to refrain from driving vehicles or working with complex equipment until such unwanted reactions are resolved.

Drug Interactions

Treatment with Roncoleukin can be combined with treatment with all other medicines.

When using Roncoleukin against the background of long-term therapy with glucocorticosteroids (GCS), the activity of the drug may decrease.

Roncoleukin should not be mixed with other medicinal products in one syringe or vial.

Analogues of the drug Roncoleukin

Roncoleukin does not have structural analogs for the active substance.

Analogues for the pharmacological group (interleukins):

• Betaleukin;
• Interleukin 1-beta;
• Proleukin.

Similar medicines:

Other medicines: